Psychemedics Corp (PMD) 14.20 $PMD
Update: Psychemedics Corp. Q3 Earnings
Bram de Haas - at Seeking Alpha - Thu Nov 20, 2:30PM CST
PMD: 14.20 (-0.29)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 14.20 (-0.29), ABT: 43.69 (-0.77), A: 39.72 (-0.90), DHR: 83.76 (-0.19), PKI: 41.73 (-0.34), OSUR: 9.49 (-0.25)
Psychemedics: Recent Results Reflect Risk Of The Brazilian Expansion
Investing Doc - at Seeking Alpha - Tue Nov 04, 7:21AM CST
PMD: 14.20 (-0.29)
Psychemedics EPS of $0.17
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 10:14AM CDT
PMD: 14.20 (-0.29)
Psychemedics Corporation Announces Record Revenues
PR Newswire - Thu Oct 30, 10:06AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September 30, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 10, 2014 to be paid on November 20, 2014. This will be the Company's 73rd consecutive quarterly dividend.
PMD: 14.20 (-0.29)
Psychemedics: Once Brazilian Legislation Is Put Into Place Shares Should Rally
Bram de Haas - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PMD: 14.20 (-0.29)
Psychemedics Has Returned 13.0% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Sep 17, 9:26AM CDT
SmarTrend identified a Downtrend for Psychemedics (NASDAQ
MD) on May 9th, 2014 at $14.87. In approximately 4 months, Psychemedics has returned 13.05% as of today's recent price of $12.93.
PMD: 14.20 (-0.29)
Update: Psychemedics Corp. Q3 Earnings
Bram de Haas - at Seeking Alpha - Thu Nov 20, 2:30PM CST
PMD: 14.20 (-0.29)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 14.20 (-0.29), ABT: 43.69 (-0.77), A: 39.72 (-0.90), DHR: 83.76 (-0.19), PKI: 41.73 (-0.34), OSUR: 9.49 (-0.25)
Psychemedics: Recent Results Reflect Risk Of The Brazilian Expansion
Investing Doc - at Seeking Alpha - Tue Nov 04, 7:21AM CST
PMD: 14.20 (-0.29)
Psychemedics EPS of $0.17
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 10:14AM CDT
PMD: 14.20 (-0.29)
Psychemedics Corporation Announces Record Revenues
PR Newswire - Thu Oct 30, 10:06AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September 30, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 10, 2014 to be paid on November 20, 2014. This will be the Company's 73rd consecutive quarterly dividend.
PMD: 14.20 (-0.29)
Psychemedics: Once Brazilian Legislation Is Put Into Place Shares Should Rally
Bram de Haas - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PMD: 14.20 (-0.29)
Psychemedics Has Returned 13.0% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Sep 17, 9:26AM CDT
SmarTrend identified a Downtrend for Psychemedics (NASDAQ
MD) on May 9th, 2014 at $14.87. In approximately 4 months, Psychemedics has returned 13.05% as of today's recent price of $12.93. PMD: 14.20 (-0.29)
